奧馬珠單抗
 奧馬珠單抗結構：（A）小鼠互補決定區和 （B） IgG1κ 人框架 | |
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | IgE Fc區域 |
| 臨床資料 | |
| 讀音 | /ˌoʊməˈlɪzumæb/ OH-mə-LI-zoo-mab |
| 商品名 | Xolair |
| 生物相似藥 | Omlyclo[1][2] |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a603031 |
| 核准狀況 | |
| 懷孕分級 |
|
| 給藥途徑 | 皮下注射 |
| ATC碼 | |
| 法律規範狀態 | |
| 法律規範 |
|
| 藥物動力學數據 | |
| 生物半衰期 | 26 days |
| 識別資訊 | |
| CAS號 | 242138-07-4  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| 化學資訊 | |
| 化學式 | C6450H9916N1714O2023S38 |
| 摩爾質量 | 145,058.53 g·mol−1 |
奧馬珠單抗（INN：Omalizumab）用於治療哮喘、鼻息肉和蕁麻疹的藥物[11] [12]。當病因是過敏且其他療法無效時可使用此藥物[11]。透過注射給藥[11]。
常見副作用包括頭痛、注射部位疼痛、瘙癢和腹痛[11]。其他副作用包括可能過敏、癌症和心血管疾病[12]。少數孕婦使用後，並無明確證據顯示對嬰兒有害[13]。它是一種單株抗體，可與免疫球蛋白E（IgE）結合並抑制免疫球蛋白E所引起的後續反應[11]。
奧馬珠單抗於 2003 年及2005在美國及歐洲取得醫療使用許可[12] [11]。
參考文獻
[編輯]- ^ 1.0 1.1 Omlyclo EPAR. European Medicines Agency. 21 March 2024 [23 March 2024]. （原始內容存檔於23 March 2024）. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ Omlyclo Product information. Union Register of medicinal products. 24 May 2024 [27 May 2024]. （原始內容存檔於27 May 2024）.
- ^ Australian Public Assessment Report for Omalizumab (PDF). Therapeutic Goods Administration. April 2021 [5 January 2023]. （原始內容存檔 (PDF)於6 January 2023）.
- ^ AusPAR Xolair Omalizumab Novartis Pharmaceuticals Australia Pty Ltd PM-2014-03868-1-5 (PDF). Therapeutic Goods Administration. 22 June 2016 [5 January 2023]. （原始內容存檔 (PDF)於13 June 2021）.
- ^ Regulatory Decision Summary - Xolair - Health Canada. Government of Canada. 14 July 2021 [5 January 2023]. （原始內容存檔於6 January 2023）.
- ^ Novartis Pharmaceuticals Canada Inc. Product Monograph: Pr Xolair Omalizumab (PDF). 26 September 2017 [5 January 2023]. （原始內容存檔 (PDF)於28 August 2021）.
- ^ Regulatory Decision Summary for Xolair. Drug and Health Products Portal. 8 February 2024 [2 April 2024]. （原始內容存檔於2 April 2024）.
- ^ Xolair 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC). (emc). 18 August 2020 [12 June 2021]. （原始內容存檔於13 June 2021）.
- ^ Xolair- omalizumab injection, solution Xolair PFS- omalizumab injection, solution. DailyMed. 11 May 2020 [6 December 2020]. （原始內容存檔於28 November 2020）.
- ^ Xolair EPAR. European Medicines Agency (EMA). 17 September 2018 [12 June 2021]. （原始內容存檔於13 June 2021）.
- ^ 11.0 11.1 11.2 11.3 11.4 11.5 Xolair EPAR. European Medicines Agency (EMA). [12 June 2021]. （原始內容存檔於13 June 2021）.
- ^ 12.0 12.1 12.2 Omalizumab Monograph for Professionals. Drugs.com. [8 November 2021]. （原始內容存檔於11 January 2020） （英語）.
- ^ Omalizumab (Xolair) Use During Pregnancy. Drugs.com. [8 November 2021]. （原始內容存檔於4 December 2020） （英語）.
